EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cardiovascular toxicity risk assessment of tyrosine kinase inhibitors: a pharmacovigilance study using the VigiBase database

Yusuke Igawa, Hirofumi Hamano, Satoru Esumi, Tatsuaki Takeda, Makoto Kajizono, Ryo Kikuoka, Ikuya Kimura, Yoshito Zamami

Frontiers in Pharmacology · 02.12.2024 · 15

DOI: 10.3389/fphar.2024.1472008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 02.12.2024. Verfasst von Yusuke Igawa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Pharmacy, Okayama University, Okayama, Japan. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Advances in the early detection and treatment of cancer have significantly improved the prognosis of patients with cancer. Tyrosine kinase inhibitors (TKIs) are effective targeted treatments for various malignancies that act by inhibiting kinase activity. Although these drugs share a common mechanism of action, they differ in their targeted kinases, pharmacokinetics, and side effects. TKIs can cause cardiovascular side effects, which adversely affect the prognosis of cancer survivors. This study aimed to assess the risk of cardiac toxicity associated with TKIs using the World Health Organization Global Database, VigiBase.

Methods

We conducted a cross-sectional analysis of data from VigiBase, a comprehensive global database of suspected drug reactions. The dataset included reports up to December 2022. We identified patients treated with Food and Drug Administration-approved TKIs and analyzed their age and sex data. The primary outcome was cardiovascular impairment, defined by 21 preferred terms in the Medical Dictionary for Regulatory Activities Terminology version 25.1. Disproportionality analysis using the reported odds ratio was performed to detect adverse cardiovascular signals. Statistical analyses were conducted using R 3.3.2, with a P-value <0.05 considered significant.

Results

Of the 32, 520, 983 reports in VigiBase, 23, 181, 539 were eligible for the analysis. Significant cardiovascular signals were identified for 17 TKIs, including erlotinib, gefitinib, and imatinib. Stratified analyses revealed potential sex- and age-related differences in the risk of adverse events. Heatmaps indicated significant signals for drugs such as lapatinib in males and gefitinib in younger patients.

Discussion

Our findings indicate that some TKIs, particularly those classified as VEGFR, BCR-ABL, and BTK, pose similar risks of cardiotoxicity, while others, including EGFR, HER2, and ALK TKIs, exhibit varied risk profiles. These results underscore the importance of individualized risk assessment and management of TKI-treated patients. In conclusion, this study provides valuable insights into the cardiotoxic risk of TKIs, which is essential for developing tailored treatment plans.

Schlagwörter

Stichwörter der Autor:innen

VigiBasecancercardiotoxicitydatabasetyrosine kinase inhibitors

Autor:innen und Institutionen

  • Department of Clinical Pharmacology and Pharmacy, Okayama University, Okayama, Japan.
  • Department of Pharmacy, Okayama University Hospital, Okayama, Japan.
  • Department of Clinical Drug Evaluation, Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe, Japan.
  • Department of Education and Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Okayama University, Okayama, Japan.
  • Department of Pharmacy, Okayama City Hospital, Okayama, Japan.

Zitieren

APA

Igawa, Y., Hamano, H., Esumi, S., Takeda, T., Kajizono, M., Kikuoka, R., Kimura, I., & Zamami, Y. (2024). Cardiovascular toxicity risk assessment of tyrosine kinase inhibitors: a pharmacovigilance study using the VigiBase database. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1472008

Vancouver

Igawa Y, Hamano H, Esumi S, Takeda T, Kajizono M, Kikuoka R, et al. Cardiovascular toxicity risk assessment of tyrosine kinase inhibitors: a pharmacovigilance study using the VigiBase database. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1472008

BibTeX
@article{Igawa2024,
  author = {Igawa, Yusuke and Hamano, Hirofumi and Esumi, Satoru and Takeda, Tatsuaki and Kajizono, Makoto and Kikuoka, Ryo and Kimura, Ikuya and Zamami, Yoshito},
  title = {Cardiovascular toxicity risk assessment of tyrosine kinase inhibitors: a pharmacovigilance study using the VigiBase database},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1472008}
}
Kostenlos starten →